Skip to content

Effect of perioperative continuous infusion of dexmedetomidine on postoperative delirium in elderly patients undergoing hip fracture surgery: a randomised, double-blind, placebo-control multicenter clinical trial

Effect of perioperative continuous infusion of dexmedetomidine on postoperative delirium in elderly patients undergoing hip fracture surgery: a randomised, double-blind, placebo-control multicenter clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065924
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative delirium

Interventions

Dex-group:continuous infusion of dexmedetomidine
placebo-group:continuous infusion of normal saline

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Elderly patients with hip fractures scheduled for surgical treatment, including femoral neck fractures, intertrochanteric fractures, and fractures less than 5 cm below the lesser trochanter (generally considered as the upper 1/3 of the femoral shaft); 2. Aged >= 65 years; 3. ASA I-III; 4. Voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Compound injury: combined with multiple fractures, such as head, chest, pelvis, limbs and other parts of the hip trauma; 2. Patients with a history of diagnosed Alzheimer's disease; 3. Patients with a history of diagnosed Parkinson disease; 4. The patient has a diagnosed psychiatric history and/or is taking psychiatric drugs; 5. Patients who have developed delirium before surgery or are using drugs (e.g., olanzapine) for delirium); 6. Patients with previous history of alpha 2 receptor agonist allergy or drug resistance; 7. Patients who are using alpha 2-receptor agonists (e.g., clonidine); 8. Patients with a history of acute cerebrovascular disease (stroke or cerebral hemorrhage occurring within 6 months); 9. Patients with 2 degree or 3 degree atrioventricular block or bradycardia and heart rate < 50 BPM on admission; 10. Unable to communicate normally, language barrier; 11. Patients who needed to take sedation or were in a coma after surgery could not complete the follow-up; 12. Have participated in other clinical investigators.

Design outcomes

Primary

MeasureTime frame
postoperative delirium;

Secondary

MeasureTime frame
degree of postoperative delirium;pain after surgery;

Countries

China

Contacts

Public ContactLi Jinbao

Shanghai General Hospital

lijinbaoshanghai@163.com+86 150 2192 8910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026